Mark E. Burkard, MD, PhD close
Mark E. Burkard, MD, PhD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Mark E. Burkard, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Mark Burkard is an assistant professor of medicine in the Hematology-Oncology section of the UW School of Medicine and Public Health and is a member of the UW Health Breast Center. Dr. Burkard received his medical degree and PhD in chemistry from the University of Rochester. He subsequently trained in internal medicine at New York Hospital-Cornell University and in medical oncology at Memorial Sloan-Kettering Cancer Center. During his oncology fellowship, he studied cell cycle enzymes as novel targets for cancer therapy. He is board certified in Internal Medicine and Medical Oncology. As an oncologist, his clinical practice and research interest is in breast cancer and experimental therapeutics.


Medical Oncology

Breast Cancer


UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 266-6400 | (800) 323-8942 | Map
University Hospital
(608) 266-6400 | (800) 323-8942 | Map

Hospital Affiliation(s)

University Hospital
Veterans Hospital - Wm. S. Middleton Memorial

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship Memorial Sloan-Kettering Cancer Center, New York, NY
Medical School University of Rochester School of Medicine, Rochester, NY

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. Burkard is interested in targeted therapy directed at protein kinases. His laboratory seeks to link therapies with their targets within cancer cells using genetic tools, and to identify patients whose cancers are most likely to benefit from particular drugs. These studies will be used to inform clinical development of novel agents. Dr. Burkard is part of the breast cancer disease oriented working group.

PubMed Articles
Fricke SL Payne SN Favreau PF Kratz JD Pasch CA Foley TM Yueh AE Van De Hey DR Depke MG Korkos DP Sha GC DeStefanis RA Clipson L Burkard ME Lemmon KK Parsons BM Kenny PA Matkowskyj KA Newton MA Skala MC Deming DA MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers. Mol Cancer Ther . 2018 Nov 13;
[PubMed ID: 30425131]
Burkard ME Golden RN Shared Knowledge in Precision Cancer Care. WMJ . 2018 Oct;117(4):178-179
[PubMed ID: 30407771]
Jin N Burkard ME MACROD2, an Original Cause of CIN? Cancer Discov . 2018 Aug;8(8):921-923
[PubMed ID: 30076143]
Kratz J Burkard M O'Meara T Pusztai L Veitch Z Bedard PL Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer. Am Soc Clin Oncol Educ Book . 2018 May 23;(38):56-64
[PubMed ID: 30231387]
Denu RA Shabbir M Nihal M Singh CK Longley BJ Burkard ME Ahmad N Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Mol Cancer Res . 2018 Mar;16(3):517-527
[PubMed ID: 29330283]
Shah RA Bennett DD Burkard ME Photosensitive lichenoid skin reaction to capecitabine. BMC Cancer . 2017 Dec 19;17(1):866
[PubMed ID: 29258457]
Ma CX Suman V Goetz MP Northfelt D Burkard ME Ademuyiwa F Naughton M Margenthaler J Aft R Gray R Tevaarwerk A Wilke L Haddad T Moynihan T Loprinzi C Hieken T Barnell EK Skidmore ZL Feng YY Krysiak K Hoog J Guo Z Nehring L Wisinski KB Mardis E Hagemann IS Vij K Sanati S Al-Kateb H Griffith OL Griffith M Doyle L Erlichman C Ellis MJ A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer. Clin Cancer Res . 2017 Nov 15;23(22):6823-6832
[PubMed ID: 28874413]
Wu CG Chen H Guo F Yadav VK Mcilwain SJ Rowse M Choudhary A Lin Z Li Y Gu T Zheng A Xu Q Lee W Resch E Johnson B Day J Ge Y Ong IM Burkard ME Ivarsson Y Xing Y PP2A-B' holoenzyme substrate recognition, regulation and role in cytokinesis. Cell Discov . 2017;3:17027
[PubMed ID: 28884018]
Denu RA Burkard ME Synchronous Bilateral Breast Cancer in a Patient With Nager Syndrome. Clin Breast Cancer . 2017 Jun;17(3):e151-e153
[PubMed ID: 28139434]
Tevaarwerk AJ Hocking WG Zeal JL Gribble M Seaborne L Buhr KA Wisinski KB Burkard ME Wiegmann DA Sesto ME Accuracy and Thoroughness of Treatment Summaries Provided as Part of Survivorship Care Plans Prepared by Two Cancer Centers. J Oncol Pract . 2017 May;13(5):e486-e495
[PubMed ID: 28221896]
Burkard ME Deming DA Lauring J Using cancer genomics to guide clinical decisions. Cancer . 2017 Apr 15;123(8):1288-1291
[PubMed ID: 28253425]
Burkard ME Weaver BA Tuning Chromosomal Instability to Optimize Tumor Fitness. Cancer Discov . 2017 Feb;7(2):134-136
[PubMed ID: 28167614]
Rampurwala M Wisinski KB Burkard ME Ehsani S O'Regan RM Carmichael L Kim K Kolesar J Tevaarwerk AJ Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Invest New Drugs . 2017 Feb;35(1):87-94
[PubMed ID: 27826831]
Kim H Johnson JM Lera RF Brahma S Burkard ME Anillin Phosphorylation Controls Timely Membrane Association and Successful Cytokinesis. PLoS Genet . 2017 Jan;13(1):e1006511
[PubMed ID: 28081137]
Wisinski KB Xu W Tevaarwerk AJ Saha S Kim K Traynor A Dietrich L Hegeman R Patel D Blank J Harter J Burkard ME Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. Clin Breast Cancer . 2016 Aug;16(4):256-61
[PubMed ID: 27133732]
Wisinski KB Tevaarwerk AJ Burkard ME Rampurwala M Eickhoff J Bell MC Kolesar JM Flynn C Liu G Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res . 2016 Jun 1;22(11):2659-67
[PubMed ID: 27026198]
Lera RF Potts GK Suzuki A Johnson JM Salmon ED Coon JJ Burkard ME Decoding Polo-like kinase 1 signaling along the kinetochore-centromere axis. Nat Chem Biol . 2016 Jun;12(6):411-8
[PubMed ID: 27043190]
Lasek AL McPherson BM Trueman NG Burkard ME The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation. PLoS One . 2016;11(2):e0150225
[PubMed ID: 26919439]
Denu RA Zasadil LM Kanugh C Laffin J Weaver BA Burkard ME Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer. BMC Cancer . 2016 Jan 29;16:47
[PubMed ID: 26832928]
Choudhary A Zachek B Lera RF Zasadil LM Lasek A Denu RA Kim H Kanugh C Laffin JJ Harter JM Wisinski KB Saha S Weaver BA Burkard ME Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer. Mol Cancer Ther . 2016 Jan;15(1):48-59
[PubMed ID: 26586723]